The story of Sildenafil presents a nuanced case for investors in the pharmaceutical sector. While initially a blockbuster success, producing huge profits, the intellectual property lapse and the subsequent flood of off-brand alternatives have drastically impacted revenue. This poses questions about the ongoing sustainability of similar therapeutic